

Special Issue

Acquired Resistance and Malignant Progression of Lung Adenocarcinoma

Message from the Guest Editor

Lung adenocarcinoma is the most common subtype of lung cancer. Thanks to the advances in molecular oncology, a number of driver genes have been identified in lung adenocarcinoma, and appropriate inhibitors have been developed against each molecular target. Now, lung adenocarcinoma is the best solid cancer to which targeted therapy is established and clinically available. However, no available drugs against cancer invasion and metastasis are currently developed partly due to the complexity of signaling, spreading to the whole body, and difficulty in assessment of the inhibitory effect in invasion and metastasis. Thus, elucidation of cell signaling involved in resistance, invasion, and metastasis by novel approaches and development of multidisciplinary treatment are prerequisites to overcome lung adenocarcinoma. The primary focus of this topic will be cell signaling and context in acquired resistance of lung adenocarcinoma against targeted therapy. In addition, the reviews and original articles will explore the mechanisms and signaling of cancer invasion and metastasis from the viewpoint of malignant progression and resistance to the treatment of lung adenocarcinoma.

Guest Editor

Dr. Yoshinori Murakami

Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Deadline for manuscript submissions

closed (1 September 2021)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/53160

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).